OBJECTIVES: To compare the long-term, prostate-specific antigen relapse-free survival outcome and incidence of toxicity for patients with low-risk prostate cancer who underwent brachytherapy or intensity-modulated radiotherapy (RT). METHODS: A total of 729 consecutive patients underwent brachytherapy (n = 448; prescription dose 144 Gy) or intensity-modulated RT alone (n = 281; prescription dose 81 Gy). The prostate-specific antigen relapse-free survival using the nadir plus 2 ng/mL definition and late toxicity using the National Cancer Institute's Common Terminology Criteria for Adverse Events were determined. RESULTS: The 7-year prostate-specific antigen relapse-free survival rate for the brachytherapy and intensity-modulated RT groups was 95% and 89% for low-risk patients, respectively (P = .004). Cox regression analysis demonstrated that brachytherapy was associated with improved prostate-specific antigen relapse-free survival, even after adjustment for other variables. The incidence of metastatic disease between treatment sessions was low for both treatment groups. Late grade 2 gastrointestinal toxicity was observed in 5.1% and 1.4% of the brachytherapy and intensity-modulated RT groups, respectively (P = .02). No significant differences were seen between treatment groups for late grade 3 or greater rectal complications (brachytherapy 1.1% and intensity-modulated RT 0%; P = .19). Late grade 2 urinary toxicity occurred more often in the brachytherapy group than in the intensity-modulated RT group (15.6% and 4.3%, respectively; P < .0001). No significant differences were seen between the 2 treatment groups for late grade 3 urinary toxicity (brachytherapy 2.2% and intensity-modulated RT 1.4%; P = .62). CONCLUSIONS: Among low-risk prostate cancer patients, the 7-year biochemical tumor control was superior for intraoperatively planned brachytherapy compared with high-dose intensity-modulated RT. Although significant toxicities were minimal for both groups, modest, but significant, increases in grade 2 urinary and rectal symptoms were noted for brachytherapy compared with intensity-modulated RT. Published by Elsevier Inc.
OBJECTIVES: To compare the long-term, prostate-specific antigen relapse-free survival outcome and incidence of toxicity for patients with low-risk prostate cancer who underwent brachytherapy or intensity-modulated radiotherapy (RT). METHODS: A total of 729 consecutive patients underwent brachytherapy (n = 448; prescription dose 144 Gy) or intensity-modulated RT alone (n = 281; prescription dose 81 Gy). The prostate-specific antigen relapse-free survival using the nadir plus 2 ng/mL definition and late toxicity using the National Cancer Institute's Common Terminology Criteria for Adverse Events were determined. RESULTS: The 7-year prostate-specific antigen relapse-free survival rate for the brachytherapy and intensity-modulated RT groups was 95% and 89% for low-risk patients, respectively (P = .004). Cox regression analysis demonstrated that brachytherapy was associated with improved prostate-specific antigen relapse-free survival, even after adjustment for other variables. The incidence of metastatic disease between treatment sessions was low for both treatment groups. Late grade 2 gastrointestinal toxicity was observed in 5.1% and 1.4% of the brachytherapy and intensity-modulated RT groups, respectively (P = .02). No significant differences were seen between treatment groups for late grade 3 or greater rectal complications (brachytherapy 1.1% and intensity-modulated RT 0%; P = .19). Late grade 2 urinary toxicity occurred more often in the brachytherapy group than in the intensity-modulated RT group (15.6% and 4.3%, respectively; P < .0001). No significant differences were seen between the 2 treatment groups for late grade 3 urinary toxicity (brachytherapy 2.2% and intensity-modulated RT 1.4%; P = .62). CONCLUSIONS: Among low-risk prostate cancerpatients, the 7-year biochemical tumor control was superior for intraoperatively planned brachytherapy compared with high-dose intensity-modulated RT. Although significant toxicities were minimal for both groups, modest, but significant, increases in grade 2 urinary and rectal symptoms were noted for brachytherapy compared with intensity-modulated RT. Published by Elsevier Inc.
Authors: Jonathan D Tward; Christopher M Lee; Lisa M Pappas; Aniko Szabo; David K Gaffney; Dennis C Shrieve Journal: Cancer Date: 2006-11-15 Impact factor: 6.860
Authors: David C Miller; Martin G Sanda; Rodney L Dunn; James E Montie; Hector Pimentel; Howard M Sandler; William P McLaughlin; John T Wei Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: M J Zelefsky; K E Wallner; C C Ling; A Raben; T Hollister; T Wolfe; A Grann; P Gaudin; Z Fuks; S A Leibel Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Stephen Frederic Wyler; Daniel Stephan Engeler; Wolfhart Seelentag; Gerhard Ries; Hans-Peter Schmid Journal: Urol Int Date: 2009-01-20 Impact factor: 2.089
Authors: Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen Journal: Int J Radiat Oncol Biol Phys Date: 2002-08-01 Impact factor: 7.038
Authors: Howard Thames; Deborah Kuban; Larry Levy; Eric M Horwitz; Patrick Kupelian; Alvaro Martinez; Jeffrey Michalski; Thomas Pisansky; Howard Sandler; William Shipley; Michael Zelefsky; Anthony Zietman Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-15 Impact factor: 7.038
Authors: W J Morris; M Keyes; D Palma; I Spadinger; M R McKenzie; A Agranovich; T Pickles; M Liu; W Kwan; J Wu; E Berthelet; H Pai Journal: Urology Date: 2009-01-24 Impact factor: 2.649
Authors: George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin Journal: Can Urol Assoc J Date: 2013 May-Jun Impact factor: 1.862
Authors: Mira Keyes; Juanita Crook; W James Morris; Gerard Morton; Tom Pickles; Nawaid Usmani; Eric Vigneault Journal: Can Urol Assoc J Date: 2013 Jan-Feb Impact factor: 1.862
Authors: Jose Luis Guinot; Jose Vicente Ricós; Maria Isabel Tortajada; Miguel Angel Santos; Juan Casanova; Jose Clemente; Josefa Samper; Paula Santamaría; Leoncio Arribas Journal: J Contemp Brachytherapy Date: 2015-08-18